التفاصيل البيبلوغرافية
| العنوان: |
Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses |
| المؤلفون: |
Saleem, Benazir, Ross, Rebecca L, Bissell, Lesley-Anne, Aslam, Aamir, Mankia, Kulveer, Duquenne, Laurence, Corsadden, Diane, Carter, Clive, Hughes, Pam, Nadat, Fatima A, Mulipa, Panji, Lobb, Mark, Clarke, Brendan, Mbara, Katie, Morton, Ruth, Dibb, Sophie, Chowdhury, Rahaymin, Newton, Darren, Pike, Alexandra, Kakkar, Vishal, Savic, Sinisia, DelGaldo, Francesco, Emery, Paul |
| المساهمون: |
Leeds Hospital Charitable Foundation, NIHR Biomedical Research Centre, Eli Lilly and Company |
| المصدر: |
RMD Open ; volume 8, issue 1, page e002050 ; ISSN 2056-5933 |
| بيانات النشر: |
BMJ |
| سنة النشر: |
2022 |
| الوصف: |
Objectives To assess antibody and T cell responses to SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on disease-modifying antirheumatic drugs (DMARDs). Methods This prospective study recruited 100 patients with RA on a variety of DMARDs for antibody and T cell analysis, pre-vaccination and 4 weeks post-vaccination. Positive antibody response was defined as sera IgG binding to ≥1 antigen. Those that remained seronegative after first vaccination were retested 4 weeks after second vaccination; and if still seronegative after vaccination three. A T cell response was defined an ELISpot count of ≥7 interferon (IFN)γ-positive cells when exposed to spike antigens. Type I IFN activity was determined using the luminex multiplex assay IFN score. Results After vaccine one, in patients without prior SARS-CoV-2 exposure, 37/83 (45%) developed vaccine-specific antibody responses, 44/83 (53%) vaccine-specific T cell responses and 64/83 (77%) developed either antibody or T cell responses. Reduced seroconversion was seen with abatacept, rituximab (RTX) and those on concomitant methotrexate (MTX) compared to 100% for healthy controls (p<0.001). Better seroconversion occurred with anti-tumour necrosis factor (TNF) versus RTX (p=0.012) and with age ≤50 (p=0.012). Pre-vaccine SARS-CoV-2 exposure was associated with higher quantitative seroconversion (≥3 antibodies) (p<0.001). In the subgroup of non-seroconverters, a second vaccination produced seroconversion in 54% (19/35), and after a third in 20% (2/10). IFN score analysis showed no change post-vaccine. Conclusion Patients with RA on DMARDs have reduced vaccine responses, particularly on certain DMARDs, with improvement on subsequent vaccinations but with approximately 10% still seronegative after three doses. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1136/rmdopen-2021-002050 |
| الإتاحة: |
https://doi.org/10.1136/rmdopen-2021-002050Test |
| حقوق: |
http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: |
edsbas.A408D502 |
| قاعدة البيانات: |
BASE |
